US 12,128,047 B2
TLR7 agonist and pharmaceutical combination thereof for treating lung cancer
Xiquan Zhang, Jiangsu (CN); Ling Yang, Jiangsu (CN); Ying Zhang, Jiangsu (CN); Mincheng Zhang, Jiangsu (CN); Wei Song, Jiangsu (CN); and Hongjiang Xu, Jiangsu (CN)
Assigned to CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., Jiangsu (CN)
Appl. No. 17/058,979
Filed by CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., Jiangsu (CN)
PCT Filed May 24, 2019, PCT No. PCT/CN2019/088360
§ 371(c)(1), (2) Date Nov. 25, 2020,
PCT Pub. No. WO2019/223788, PCT Pub. Date Nov. 28, 2019.
Claims priority of application No. 201810560770.X (CN), filed on May 25, 2018.
Prior Publication US 2021/0220362 A1, Jul. 22, 2021
Int. Cl. A61K 31/519 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/519 (2013.01) [A61P 35/00 (2018.01)] 15 Claims
 
1. A pharmaceutical combination, comprising a TLR7 agonist or a pharmaceutically acceptable salt thereof, and anlotinib or a pharmaceutically acceptable salt thereof, wherein the TLR7 agonist is 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine

OG Complex Work Unit Chemistry